Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade

Mounting evidence suggests that inhibition of protein phosphatase-2A (PP2A), a serine/threonine phosphatase, could enhance anticancer immunity. However, drugs targeting PP2A are not currently available. Here, we report that a PP2A inhibitor, LB-100, when combined with anti-PD-1 (aPD-1) blockade can...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Winson S., Wang, Herui, Maggio, Dominic, Kovach, John S., Zhang, Qi, Song, Qi, Marincola, Francesco M., Heiss, John D., Gilbert, Mark R., Lu, Rongze, Zhuang, Zhengping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974350/
https://www.ncbi.nlm.nih.gov/pubmed/29844427
http://dx.doi.org/10.1038/s41467-018-04425-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974350/
https://www.ncbi.nlm.nih.gov/pubmed/29844427
http://dx.doi.org/10.1038/s41467-018-04425-z

Ejemplares similares